SPRO

Spero Therapeutics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · sperotherapeutics.com

$2.50

Mkt Cap $144.7M

52w Low $0.57 72.8% of range 52w High $3.22

50d MA $2.50 200d MA $2.31

P/E (TTM) 16.5x

EV/EBITDA -3881.6x

P/B 2.4x

Debt/Equity 0.1x

ROE 14.5%

P/FCF -10.3x

RSI (14) —

ATR (14) —

Beta 1.45

50d MA $2.50

200d MA $2.31

Avg Volume 377.9K

About

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Mar 26, 2026	AMC	-0.20	0.53	+365.0%	2.37	-3.0%	-1.7%	-5.5%	-1.3%	+3.4%	+2.5%	+12.7%	—
Nov 13, 2025	AMC	-0.25	-0.13	+48.0%	2.44	-2.0%	-1.2%	-0.4%	+1.2%	-2.5%	-7.4%	-6.1%	—
Aug 12, 2025	AMC	-0.38	-0.03	+92.1%	2.36	-8.9%	-17.8%	-16.1%	-19.1%	-19.1%	-22.0%	-17.4%	—
May 13, 2025	AMC	-0.55	-0.25	+54.5%	0.69	+1.4%	-5.8%	-5.6%	-5.7%	-0.1%	-1.4%	+318.8%	—
Mar 27, 2025	AMC	-0.35	-0.38	-8.6%	0.86	-1.2%	-10.9%	-16.3%	-19.3%	-17.9%	-27.5%	-17.5%	—
Nov 14, 2024	AMC	-0.27	-0.32	-18.5%	1.25	+0.0%	-5.6%	-8.8%	-7.2%	-4.0%	-4.8%	-14.4%	—
Aug 5, 2024	AMC	-0.35	-0.33	+5.7%	1.34	+3.0%	-5.2%	-8.2%	-6.0%	-4.5%	-3.7%	-2.2%	—
May 15, 2024	AMC	-0.07	-0.24	-242.9%	1.62	-1.2%	-3.1%	-1.9%	-3.7%	-6.8%	-6.8%	-16.0%	—
Mar 13, 2024	AMC	-0.10	0.96	+1060.0%	1.66	+10.2%	+4.8%	+7.8%	+4.2%	+7.2%	+6.0%	-1.2%	—
Nov 13, 2023	AMC	-0.15	0.02	+113.3%	1.11	+2.7%	-1.8%	+2.7%	+4.5%	+7.2%	+10.8%	+16.2%	—
Aug 10, 2023	AMC	-0.29	-0.23	+20.7%	1.45	+1.4%	-3.4%	-5.5%	-6.9%	-9.7%	-7.6%	-8.3%	—
May 11, 2023	AMC	-0.35	-0.25	+28.6%	1.92	-1.0%	-3.6%	-2.6%	-6.8%	-5.2%	-6.2%	-8.9%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Jan 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.86	$0.85	-1.2%	+1.2%	-0.4%	-6.6%	-12.4%	+2.0%
Dec 20	Evercore ISI	Downgrade	Outperform → In Line	—	$1.00	$0.99	-0.8%	-4.3%	-7.5%	-6.1%	-5.4%	+3.2%
Dec 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.14	$1.13	-0.9%	-0.9%	+1.8%	+3.5%	+1.8%	+2.6%
Nov 18	TD Cowen	Downgrade	Buy → Hold	—	$1.18	$1.20	+1.7%	-3.4%	-1.7%	+1.7%	+0.8%	-1.7%
Nov 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.18	$1.16	-1.7%	+9.3%	+11.0%	+11.0%	+11.0%	+11.9%
Oct 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.31	$1.33	+1.5%	-1.5%	-0.8%	-0.8%	-5.3%	-5.3%
Aug 6	TD Cowen	Upgrade	Hold → Buy	—	$1.34	$1.38	+3.0%	-5.2%	-8.2%	-6.0%	-4.5%	-3.7%
Aug 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.34	$1.38	+3.0%	-5.2%	-8.2%	-6.0%	-4.5%	-3.7%
May 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.62	$1.60	-1.2%	-3.1%	-1.9%	-3.7%	-6.8%	-6.8%
Mar 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.79	$1.70	-5.0%	-3.4%	-0.6%	-1.7%	-3.4%	-2.2%
Nov 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.11	$1.14	+2.7%	-1.8%	+2.7%	+4.5%	+7.2%	+10.8%
Sep 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.52	$1.52	+0.0%	-5.9%	-9.2%	-11.8%	-10.5%	-12.5%
Aug 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.40	$1.41	+0.7%	-2.1%	-3.6%	-6.4%	-4.3%	-8.6%
Aug 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.63	$1.62	-0.6%	-6.7%	-5.5%	-7.4%	-7.4%	-8.0%
Jul 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.48	$1.48	+0.0%	-1.4%	-2.0%	-2.0%	-4.7%	-4.1%
Apr 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.51	$1.51	+0.0%	+3.3%	+7.3%	+7.3%	+13.2%	+13.9%
Sep 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.97	$2.00	+1.5%	+6.1%	+2.5%	+4.1%	+0.0%	+1.5%
Sep 23	Evercore ISI	Upgrade	In Line → Outperform	—	$2.20	$2.27	+3.2%	-10.5%	-5.0%	-8.2%	-6.8%	-10.5%
Aug 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.78	$0.78	+0.0%	+15.9%	+14.9%	+37.2%	+32.1%	+26.0%
May 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.38	$1.37	-0.7%	-3.6%	-10.9%	-13.0%	-13.0%	-10.1%
May 20	Berenberg	Downgrade	Buy → Hold	—	$1.44	$1.41	-2.1%	-4.2%	-7.6%	-14.6%	-16.7%	-16.7%
May 17	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$1.71	$1.77	+3.5%	-3.5%	-15.8%	-15.8%	-19.3%	-22.2%
May 4	Cowen & Co.	Downgrade	Outperform → Market Perform	—	$1.85	$1.62	-12.4%	-5.4%	-0.5%	+11.9%	+2.2%	-4.9%
May 4	Evercore ISI	Downgrade	Outperform → In Line	—	$1.85	$1.62	-12.4%	-5.4%	-0.5%	+11.9%	+2.2%	-4.9%
Apr 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.11	$6.02	-1.5%	-6.9%	-2.6%	-3.4%	-10.5%	-10.3%
Mar 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.38	$8.72	+4.1%	+1.7%	+3.2%	+0.7%	+0.2%	-2.7%
Oct 1	Oppenheimer	Downgrade	Outperform → Perform	—	$18.41	$17.57	-4.6%	-4.7%	-1.8%	+2.0%	-6.0%	-7.1%
Jan 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.75	$18.65	+5.1%	+5.9%	+6.8%	+5.1%	+1.4%	+2.5%
Dec 16	Berenberg	Maintains	Buy → Buy	—	$17.40	$17.87	+2.7%	+5.5%	+6.5%	+1.7%	+9.2%	+25.0%
Nov 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.18	$15.86	+4.5%	+4.7%	+4.7%	+4.9%	+10.2%	+9.2%
Sep 29	Evercore ISI	Maintains	Outperform → Outperform	—	$9.30	$10.22	+9.9%	+7.0%	+20.0%	+25.3%	+29.7%	+34.0%
May 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.78	$11.85	+0.6%	+8.2%	+1.9%	-0.7%	-0.7%	+1.3%
Mar 17	Stifel	Maintains	Buy → Buy	—	$5.27	$5.60	+6.3%	+28.8%	+17.5%	+24.3%	+10.2%	+12.5%
Nov 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.71	$10.88	+1.6%	-2.0%	-0.1%	-1.3%	-1.7%	-2.1%
Nov 5	H.C. Wainwright	Maintains	Buy → Buy	—	$10.71	$10.88	+1.6%	-2.0%	-0.1%	-1.3%	-1.7%	-2.1%
Sep 9	Janney Capital	Maintains	Buy → Buy	—	$9.98	$10.74	+7.6%	+11.2%	+17.7%	+25.8%	+24.6%	+19.6%
Oct 16	Bank of America	Downgrade	Neutral → Underperform	—	$9.76	$9.33	-4.4%	-12.8%	-12.0%	-12.5%	-12.7%	-13.8%
Oct 16	BofA Securities	Downgrade	Neutral → Underperform	—	$9.76	$9.33	-4.4%	-12.8%	-12.0%	-12.5%	-12.7%	-13.8%
May 11	H.C. Wainwright	Maintains	Buy → Buy	—	$11.59	$12.58	+8.5%	+3.9%	-1.6%	+5.5%	+4.3%	+4.7%
Feb 9	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$11.97	$12.08	+0.9%	-0.8%	-3.4%	-6.4%	-16.5%	-16.8%
Nov 27	Cowen & Co.	Maintains	Outperform → Outperform	—	$13.86	$14.26	+2.9%	+1.5%	-1.7%	-7.8%	-13.8%	-12.4%
Nov 27	Stifel Nicolaus	Maintains	Buy → Buy	—	$13.86	$14.26	+2.9%	+1.5%	-1.7%	-7.8%	-13.8%	-12.4%
Nov 27	Bank of America	Maintains	Neutral → Neutral	—	$13.86	$14.26	+2.9%	+1.5%	-1.7%	-7.8%	-13.8%	-12.4%

Recent Filings

8-K

Unknown — 8-K Filing

SPRO's tebipenem partnership with GSK suggests significant commercial potential in anti-infectives if approved, but investors should monitor clinical progress and regulatory timelines since the company remains clinical-stage with limited revenue visibility.

Mar 26

Data updated apr 27, 2026 2:39am · Source: massive.com